View clinical trials related to Huntington Disease.
Filter by:In this project investigators will evaluate the benefits of contemporary dance training using a comprehensive test battery combining standard neuropsychological batteries, psychological questionnaires on emotion, empathy and quality of life, structural magnet-resonance tomography (MRI), as well as psychophysical tests on movement recognition and agency, the sense of being in control of one's own movement. For 10 years now two experienced dancer‐choreographers lead dance workshops for people with Huntington's Disease (HD) and their family and caregivers in Paris. This project will evaluate objectively the effects these workshops have, by assessing a new group of 18 patients and their partners and caregivers before and after 8 month of weekly dance training. People with HD are troubled by involuntary movements, of which they are however not accurately aware, but moreover they become impaired at recognising instrumental actions in others. It is well known that observing somebody else's action and executing the same action rest on a common neural network. This might mean that improving one's own action execution can improve the observation and understanding of others' actions in turn. Here, investigators will investigate both the impact the movement impairments caused by HD might have on patients themselves as well as on their partners and caregivers, as a consequence of the fact that own and other action representations are shared. After 8 months of contemporary dance training, both groups will be tested again, in order to establish if both action execution (self) and perception (in others) have improved. Other recent psychophysics and brain imaging experiments have demonstrated how the sense of agency is composed from external cues (for example sound) of the consequences of movements, and from internal sensorimotor information that result from the action plan. Importantly, in HD the latter input might be impaired, but this has never been systematically tested. Making use of a psychophysics paradigm disentangling the two cues to agency investigators first monitor the sense of their own movement in HD, and further assess the changes in agency and in the role of these cues to agency after eight months of contemporary dance practice. Finally investigators will monitor the structural brain changes accompanying this progress, comparing the brain before and after regular dance practice and correlating action recognition psychophysics measures of agency with these changes. In sum, this project has a double impact. Firstly it will scientifically evaluate the impact of dance on the normal but especially the brain affected by a neurodegenerative disease that causes movement impairments, and establish its effect on behaviour and wellbeing. Secondly it will evaluate in patient partners and caregivers how they represent the patients' as well as their own movements and how this changes with dance practice.
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
To examine the benefits of using a video-game, Dance, Dance, Revolution, as an exercise modality to improve gait and balance in individuals with Huntington's disease.
The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.
This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the amount of drug in the blood. The study will involve healthy male volunteers.
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.
Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia. HD is characterized by brain cell death that usually begins between the ages of 30 to 50, and results in motor, cognitive and behavioral signs and symptoms. While there are medications to help relieve some of the disease symptoms, there is no known treatment to address the cognitive impairment associated with HD. Normally occurring metals in the brain play a significant role in diseases such as Alzheimer disease and more recently, HD. PBT2 is a drug designed to interrupt interactions between these biological metals and target proteins in the brain, to prevent deterioration of brain cells. PBT2, has shown in animal models, and as well as in a small group of patients with Alzheimer's disease, it may improve cognition. There is some indication in animal models of HD, that the drug may improve motor function and control and reduce the amount of brain cell degeneration. Based on these results, this clinical trial is investigating whether the drug will have similar effects with HD patients. PBT2-203 will evaluate how safe and well tolerated PBT2 is at a dose of 100 mg or 250 mg a day administered as oral daily capsules compared to a placebo over six months treatment period. The trial will also measure whether there is an effect on cognitive abilities as well as other HD symptoms including motor and overall functioning of individuals with HD.
The study aims to monitor the progression of symptoms and signs of those affected by JHD using modified UHDRS scales of motor and function (functional assessment, TFC). This will provide some basic data to analyse the usefulness of the proposed rating scales. Specifically, the initial aim is to assess these rating scales using an iterative process. There may be significant delays in diagnosis of JHD especially if the young person presents with behavioural problems. Caregivers will be asked questions to capture the number of contacts with professionals in the time between onset of concerns about the young person and the confirmation of diagnosis. Aim is to monitor the progression of symptoms and signs of those affected by JHD using modified UHDRS scales of motor and function (functional assessment, TFC). This will provide some basic data to analyse the usefulness of the proposed rating scales.